Cristin Davidson
Affiliations: | 2013 | Yeshiva University, New York, NY, United States |
Google:
"Cristin Davidson"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Steven U. Walkley | grad student | 2013 | Yeshiva University | |
| (Efficacy and mechanism of action of cyclodextrin in the treatment of Niemann-Pick type C disease.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yerger J, Cougnoux AC, Abbott CB, et al. (2022) Phenotype assessment for neurodegenerative murine models with ataxia and application to Niemann-Pick disease, type C1. Biology Open. 11 |
| Davidson CD, Gibson AL, Gu T, et al. (2021) Improved systemic AAV gene therapy with a neurotrophic capsid in Niemann-Pick disease type C1 mice. Life Science Alliance. 4 |
| Rodriguez-Gil JL, Baxter LL, Watkins-Chow DE, et al. (2021) Transcriptome of HPβCD-treated Niemann-pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics. Human Molecular Genetics |
| Cougnoux A, Fellmeth M, Gu T, et al. (2019) Maternal immune activation modifies the course of Niemann-pick disease, type C1 in a gender specific manner. Molecular Genetics and Metabolism |
| Davidson J, Molitor E, Moores S, et al. (2019) 2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids |
| Pergande MR, Nguyen TTA, Haney-Ball C, et al. (2019) Quantitative, label-free proteomics in the symptomatic Niemann-Pick, type C1 mouse model using standard flow liquid chromatography and thermal focusing electrospray ionization. Proteomics. e1800432 |
| Davidson C, Gibson A, Gu T, et al. (2019) Improved disease amelioration with combination therapy for Niemann-Pick disease type C1 Molecular Genetics and Metabolism. 126: S46 |
| Davidson C, Gibson A, Gu T, et al. (2018) Gene therapy for the treatment of Niemann-Pick disease type C1: Comparison of AAV9 to a novel serotype, AAV-PHP.B Molecular Genetics and Metabolism. 123: S36-S37 |
| Ory DS, Ottinger EA, Farhat NY, et al. (2017) Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet (London, England) |
| Yang DS, Stavrides P, Kumar A, et al. (2017) Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice. Human Molecular Genetics |